KEPPRA (Levetiracetum) VS EPIVAL (Sodium Valporate) to control generalized tonic clonic seizures.

Abstract

Objective: This present study is design to assess the efficacy and frequency of side effects with a newer anti-epileptic agent levertiracetum while comparing an older anti-epileptic, Sodium Valproate, in the patients with generalized tonic colonic epilepsy. Material & Methods: Patients with GTC epilepsy had been allocated in two groups, A and B, Group A was given Sodium valproate while group B was given levertiracetum. Study Design: Randomized Control Trial. Setting: Fatima Memorial Hospital, Lahore and Allied Hospital, Faisalabad. Period: December, 2017 to December, 2018. Results: Seventy five subjects were taking levertiracetum from three months out of which 56(74.7%)were seizures free, 15(20%) were seizure free on higher dose,6(8%) were with dizziness ,vertigo and 9(12%) were with somnolence. Fifty-four individuals were seizures free with normal dose of sodium valproate from last 3 months, and 16(21%) were seizures free on higher doses among which 53(70%) were with side effects of weight gain and 69(92%) were with hand tremors and this was the most prominent side effects among individuals who were taking sodium valproate. Conclusion: Generalized tonic colonic epilepsy is one of the most common forms of epilepsy and with the advent of newer anti-epileptic drugs like levertiracetum, such seizures can be controlled in with lesser side effects as compared to older antiepileptic agent Sodium Valproate.